The primary endpoint, outcome on the GBS Disability Score (GBS-DS) at 8 weeks, showed 29% of patients treated with ...

Annexon's tanruprubart showed significant and sustained functional gains in Guillain-Barré patients, meeting key Phase 3 ...

As it advances a monoclonal antibody targeting Guillain-Barré syndrome (GBS), Annexon Biosciences is embarking on another ...

Annexon (ANNX) presented data for its late-stage targeted therapy for GBS and showcased new disease education activities at the AAN Annual ...

While the 75 mg/kg dose tested in the study also outperformed placebo, its results were not statistically significant on the GBS-disability scale. Annexon (ANNX) said the experimental drug was ...

Also Read: Mid-Cap Firm Annexon’s Nerve Disorder Candidate Shows Promise In Pivotal Late-Stage Study The primary endpoint, GBS-Disability Scale (DS), showed that after a single infusion of ...